The Wistar Institute的动态

Exciting to see Kernal Biologics advancing mRNA technology and CAR-T therapies with presentations at the 12th International #mRNA Health Conference in Boston! Manfred Kraus and Cafer Ozdemir will be showcasing breakthrough approaches that hold promise for treating blood cancers and autoimmune disorders, as well as pioneering cell-selective mRNA designs. #Biotech #PrecisionMedicine #mRNATherapeutics #Innovation #FoundersX #VentureCapital

Happy Wednesday all! Check out this open access JEM review by Francesca Pala, Luigi D. Notarangelo, and Marita Bosticardo,?"Rediscovering the human thymus through cutting-edge technologies." https://lnkd.in/gBFUVGFQ Summary: Recent technological advances have transformed our understanding of the human thymus. Innovations such as high-resolution imaging, single-cell omics, and organoid cultures, including thymic epithelial cell (TEC) differentiation and culture, and improvements in biomaterials, have further elucidated the thymus architecture, cellular dynamics, and molecular mechanisms underlying T cell development, and have unraveled previously unrecognized levels of stromal cell heterogeneity. These advancements offer unprecedented insights into thymic biology and hold promise for the development of novel therapeutic strategies for immune-related disorders. #drugdiscovery #immunology #thymus #cancerresearch #tcelltherapy #immunooncology #scientificresearch

Imaging both subcellular details and entire biological specimens provides researchers with unprecedented insights into complex biological processes — enabling the next step in scientific progress. Prof. Dr. Matthias Gunzer and his team at the Institute for Experimental Immunology and Imaging, University Hospital Duisburg-Essen, Germany, leverage such capabilities with the UltraMicroscope Platform to reveal the intricate dynamics of immune cell behavior. Listen to the exciting work being done in Essen alongside others pioneering the field as we celebrate 35 years of Miltenyi Biotec. https://ow.ly/LNVZ50TW3K7 #MiltenyiBiotec35Years

?? Will you be attending the Cell Engager Summit??? Our team of Business Developers and scientific experts will be present at the 6th edition of the conference on May 21-23, 2024, in Boston. On Wednesday, May 22, at 11:30 a.m. EDT, Kader Thiam, our Senior Vice President - Discovery, Preclinical Models and Services, will give a presentation entitled: "How to Enhance Translatability of Immunotherapies in Preclinical Models?" ?? The presentation will focus on: ? Syngeneic humanized mouse models and #BRGSF-HIS hCD34+ reconstituted mice featuring human lymphoid and myeloid compartments? ? Characterization of the immune response in the mice ? Assessment of efficacy and safety induced by cell engagers If you plan on attending, don't miss the opportunity to connect and exchange with our team! Book your ticket to the conference here ?? https://lnkd.in/eC_yb-nV Learn more about our BRGSF-HIS mouse here ?? https://lnkd.in/eFxhmuss Learn about our syngeneic mouse models here ?? https://lnkd.in/eswQmRYD #6thcellengagersummit #cancerresearch #cellangagers

The encouraging news is that lung cancer rates are rapidly declining due to anti-smoking policies. However, there is a concerning increase in other types of cancers, such as those of the digestive system and sexual organs, especially among Generation X. Ongoing complementary studies aim to understand the reasons behind this rise to develop preventive measures: "A major new study projects that members of Generation X—people born between 1965 and 1980—have a higher rate of developing cancer than their parents and grandparents. [...] The model study, published in JAMA Network Open, sifted through cancer surveillance data collected between 1992 and 2018 on 3.8 million people in the U.S. Researchers looked for patterns in invasive cancer cases—those that have spread beyond the original site—within and among Generation X, Baby Boomers (people born in 1946–1964), the Silent Generation (1928–1945) and the Greatest Generation (1908–1927). The findings suggest that medical advances against some cancers—gained by better screening, prevention and treatment—have been overtaken by startling increases in other cancers, including colon, rectal, thyroid, ovarian and prostate cancers.? [...] Previous studies have reported that people younger than age 50 are experiencing higher rates of certain types of cancers, particularly those of the digestive system." #Health #Cancer #GenZ #Study https://lnkd.in/dAHdvSzb

Investigating the dynamics of mRNA-LNPs in mice and non-human primates: in their latest study, Christine Prost at Sanofi, Roger Le Grand at Université Paris-Saclay and collaborators employed a combination of in vivo imaging techniques to study vaccine migration from the injection site to draining lymph nodes, examining interactions with local immune cells while comparing the dynamics and biodistribution of two different LNP formulations https://lnkd.in/ewhxiDh8 Their study demonstrated how the nature and physicochemical properties of the LNP delivery vehicle, including surface characteristics and in vivo mRNA release susceptibility, influence the mRNA's in vivo distribution. An article co-authored by katia lemdani, Romain Marlin, Céline Mayet, Vladimir Perkov, Quentin PASCAL, Manon Ripoll, Francis Relouzat, Nina DHOOGE, Laetitia Bossevot, Nathalie Dereuddre-Bosquet, Gihad Dargazanli, Kevin Thibault-Duprey, Jean Haensler and Catherine Chapon #LNPs #mRNA #microscopy #imaging #biodistribution #Vesiculab

It is time to meet at the Cell Engager Summit on May 21-23, 2024, in Boston. On Wednesday, May 22, at 11:30 a.m. EDT,?Kader Thiam, our Senior Vice President - Discovery, Preclinical Models and Services, will give a presentation entitled: "How to Enhance Translatability of Immunotherapies in Preclinical Models?" ?? The presentation will focus on: ? Syngeneic humanized mouse models and?#BRGSF-HIS hCD34+ reconstituted mice featuring human lymphoid and myeloid compartments? ? Characterization of the immune response in the mice ? Assessment of efficacy and safety induced by cell engagers If you plan on attending, don't miss the opportunity to connect and exchange with our team! Book your ticket to the conference here ???https://lnkd.in/eC_yb-nV Learn more about our BRGSF-HIS mouse here ???https://lnkd.in/eFxhmuss Learn about our syngeneic mouse models here ???https://lnkd.in/eswQmRYD

Delighted to share my recent article in Cell Press iScience. In the current study, we show how network approach is better than traditional DEGs based methods. Give it a read and reach out to me if you have any queries or feedback. #CancerResearch #NCI #BreastCancer

I am thrilled to share that our latest research paper,?"Altered Elastin Turnover, Immune Response, and Age-Related Retinal Thinning in a Transgenic Mouse Model with RPE-Specific HTRA1 Overexpression", has been published in IOVS this month

Advances in #scSeq have opened up new ways to investigate the diversity of our immune system. Do blood measurements truly represent tissue immune responses? Enter the largest and most diverse #TCR study to date. #HOPE Performer Lisa Wagar and team at UC Irvine took a deep dive into the T cell landscape, profiling millions of cells from 10 donors – 20x more cells per donor at 100x greater sampling depth than in typical studies. The results? A TCR repertoire that is fundamentally different than what was previously known from blood alone, with minimal overlap between clones found in blood versus tonsils. These findings challenge our previous understanding of immune cell diversity and could transform the way we build preclinical models to test vaccines and immunotherapies. Read the full study, out as pre-print here: https://lnkd.in/eJUp4tcE Suhas Sureshchandra, PhD, Jenna Kastenschmidt, PhD Annie Moisan, Andreas Mayer, Naresha Saligrama #Tcells #scRNA #TCRseq #HOPEProgram #LifeSciences #WellcomeLeap